A Crowd Sourcing Platform for Patients With Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03530826|
Recruitment Status : Recruiting
First Posted : May 21, 2018
Last Update Posted : July 21, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Cancer||Other: No intervention|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||5000 participants|
|Target Follow-Up Duration:||10 Years|
|Official Title:||A Crowd Sourcing Platform for Patients With Cancer|
|Actual Study Start Date :||April 26, 2018|
|Estimated Primary Completion Date :||January 31, 2028|
|Estimated Study Completion Date :||January 31, 2028|
- Other: No intervention
- Change in tumor tissue molecular profiles [ Time Frame: 6 years ]Profiles of pre- and post-treatment tumor tissue will be compared.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Have been diagnosed with cancer.
- Be under the care of a physician.
- Be 18 years of age or older.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03530826
|Contact: Carl A Blau, MDfirstname.lastname@example.org|
|Contact: Kimberly A Burton, PhDemail@example.com|
|United States, Washington|
|Seattle, Washington, United States, 98136|
|Contact: Carl A Blau, MD 206-412-1787 firstname.lastname@example.org|
|Contact: Kimberly A Burton, PhD 2069482711 email@example.com|
|Principal Investigator:||Carl A Blau, MD||All4Cure|
|Responsible Party:||Carl Anthony Blau, MD, Principal Investigator, All4Cure|
|Other Study ID Numbers:||
|First Posted:||May 21, 2018 Key Record Dates|
|Last Update Posted:||July 21, 2021|
|Last Verified:||July 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Plan Description:||nonidentifiable clinical and research data may be shared with other researchers.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|